Table 2.

Baseline characteristics for participants (overall and by group allocation)

Variable	All (n=28)	Intervention (n=15)	Control (n=13)	P
Age, years	56 ±10.5 (30–69)	58.0±6.1 (43–67)	53.7±13.9 (30–69)	0.317
Race
Caucasian	24 (86%)	13 (87%)	11 (85%)	0.877
African American	4 (14%)	2 (13%)	2 (15%)
Education, years	15.1±2.9 (9–20)	14.1±2.9 (9–20)	16.3±2.5 (12–20)	0.047
Income (household)
<$10,000	3 (10.7%)	2 (13.3%)	1 (7.7%)
$10,000–$19,999	1 (3.6%)	1 (6.7%)	0 (0%)
$20,000–$34,999	2 (7.1%)	1 (6.7%)	1 (7.7%)	0.754
$35,000–$49,999	0 (0%)	0 (0%)	0 (0%)
$50,000+	22 (78.6%)	11 (73.3%)	11 (84.6%)
Months since
Diagnosis	73.9±70.7 (6–242)	86.9±81.1 (6–242)	59±55.9 (10–206)	0.307
Cancer stage
Stage 1	15 (54%)	10 (67%)	5 (39%)
Stage 2	9 (32%)	4 (27%)	5 (39%)	0.266
Stage 3	4 (14%)	1 (7%)	3 (23%)
Smoking (yes)	0 (0%)	0 (0%)	0 (0%)	1.00
Alcohol (yes)	15 (54%)	8 (53%)	7 (54%)	0.978
Drinks/week	2.1±4.7 (0–24)	2.1±6.1 (0–24)	2.0±2.4 (0–6)	0.929
Surgery (yes)	28 (100%)	15 (100%)	13 (100%)	1.00
Chemotherapy (yes)	21 (75%)	10 (67%)	11 (85%)	0.274
Radiation (yes)	22 (79%)	12 (80%)	10 (77%)	0.843
Hormonal therapy
Aromatase inhibitor	9 (32%)	6 (40%)	3 (23%)
Estrogen receptor	5 (18%)	1 (7%)	4 (31%)	0.228
None	14 (50%)	8 (53%)	6 (46%)
Lymphedema
Yes	3 (11%)	1 (7%)	2 (15.4%)
No	20 (71%)	11 (73%)	9 (69.2%)	0.743
Not Sure	5 (18%)	3 (20%)	2 (15.4%)
Beta blocker (yes)	5 (18%)	2 (13%)	3 (23%)	0.502
Post-menopausal (yes)	24 (86%)	14 (93%)	10 (77%)	0.216
Comorbidity score	2.7±2.1 (0–8)	2.7±1.9 (0–6)	2.7±2.3 (0–8)	0.938
Left arm circumference (cm)	34.41±5.9 (24.8–47.0)	34.6±5.8 (25.67–47.03)	34.2±6.2 (24.8–46.3)	0.855
Right arm circumference (cm)	34.2±5.5 (24.9–47.0)	34.3±5.3 (25.7–47.0)	34.2±5.8 (24.9–46.3)	0.968
Dietary carbohydrates (gm/day)	211.9±67.8 (105.3–342.9)	208.6±73.1 (113.7–342.9)	215.6±64.1 (105.3–293.1)	0.791

Values presented as mean ± SD (range) or n (%)